Cargando…

Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma

A 48-year-old woman with a positive BRCA1 gene mutation was diagnosed with stage 3b high-grade ovarian endometrioid carcinoma. She was treated with adjuvant carboplatin at a dose of 740 mg (AUC 6) in 3-weekly cycles. Five days after her fifth cycle of carboplatin, she awoke with new-onset blurred vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Philippa, Waqar, Salman, Yiannakis, Dennis, Raman, Vasant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934811/
https://www.ncbi.nlm.nih.gov/pubmed/24575012
http://dx.doi.org/10.1159/000357912
_version_ 1782305104080142336
author Lewis, Philippa
Waqar, Salman
Yiannakis, Dennis
Raman, Vasant
author_facet Lewis, Philippa
Waqar, Salman
Yiannakis, Dennis
Raman, Vasant
author_sort Lewis, Philippa
collection PubMed
description A 48-year-old woman with a positive BRCA1 gene mutation was diagnosed with stage 3b high-grade ovarian endometrioid carcinoma. She was treated with adjuvant carboplatin at a dose of 740 mg (AUC 6) in 3-weekly cycles. Five days after her fifth cycle of carboplatin, she awoke with new-onset blurred vision in her left eye. An ophthalmology review showed left-sided disc oedema with normal optic nerve function tests and 6/24 visual acuity. A CT scan of the head and orbits was performed which showed no evidence of metastasis or raised intracranial pressure. An autoimmune screen was performed which did not reveal any explanation for her visual symptoms. Fundus fluorescein angiography showed bilateral intense late disc leakage with no evidence of vasculitis. Her chemotherapy was stopped in view of a radiological and biochemical remission and her visual symptoms were monitored. She was also started on a tapering dose of prednisolone 40 mg daily. Five months after the initial review, she has developed left optic disc atrophy with 6/18 visual acuity, while the right eye remains asymptomatic. The diagnosis was felt to be that of carboplatin-induced unilateral disc oedema, a very rare side effect of this chemotherapy.
format Online
Article
Text
id pubmed-3934811
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-39348112014-02-26 Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma Lewis, Philippa Waqar, Salman Yiannakis, Dennis Raman, Vasant Case Rep Oncol Published online: January, 2014 A 48-year-old woman with a positive BRCA1 gene mutation was diagnosed with stage 3b high-grade ovarian endometrioid carcinoma. She was treated with adjuvant carboplatin at a dose of 740 mg (AUC 6) in 3-weekly cycles. Five days after her fifth cycle of carboplatin, she awoke with new-onset blurred vision in her left eye. An ophthalmology review showed left-sided disc oedema with normal optic nerve function tests and 6/24 visual acuity. A CT scan of the head and orbits was performed which showed no evidence of metastasis or raised intracranial pressure. An autoimmune screen was performed which did not reveal any explanation for her visual symptoms. Fundus fluorescein angiography showed bilateral intense late disc leakage with no evidence of vasculitis. Her chemotherapy was stopped in view of a radiological and biochemical remission and her visual symptoms were monitored. She was also started on a tapering dose of prednisolone 40 mg daily. Five months after the initial review, she has developed left optic disc atrophy with 6/18 visual acuity, while the right eye remains asymptomatic. The diagnosis was felt to be that of carboplatin-induced unilateral disc oedema, a very rare side effect of this chemotherapy. S. Karger AG 2014-01-10 /pmc/articles/PMC3934811/ /pubmed/24575012 http://dx.doi.org/10.1159/000357912 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: January, 2014
Lewis, Philippa
Waqar, Salman
Yiannakis, Dennis
Raman, Vasant
Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title_full Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title_fullStr Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title_full_unstemmed Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title_short Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma
title_sort unilateral optic disc papilloedema following administration of carboplatin chemotherapy for ovarian carcinoma
topic Published online: January, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934811/
https://www.ncbi.nlm.nih.gov/pubmed/24575012
http://dx.doi.org/10.1159/000357912
work_keys_str_mv AT lewisphilippa unilateralopticdiscpapilloedemafollowingadministrationofcarboplatinchemotherapyforovariancarcinoma
AT waqarsalman unilateralopticdiscpapilloedemafollowingadministrationofcarboplatinchemotherapyforovariancarcinoma
AT yiannakisdennis unilateralopticdiscpapilloedemafollowingadministrationofcarboplatinchemotherapyforovariancarcinoma
AT ramanvasant unilateralopticdiscpapilloedemafollowingadministrationofcarboplatinchemotherapyforovariancarcinoma